NCT00750360View on ClinicalTrials.gov

Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age.

PHASE4CompletedINTERVENTIONAL

Enrollment

883

Participants

Timeline

Start Date

October 3, 2003

Primary Completion Date

December 1, 2007

Study Completion Date

December 28, 2007

Conditions

Influenza

Interventions

BIOLOGICAL

FluarixTM

All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).